GlassScriptPhysician profile
Dan N Luu
NPI 1134389026
$1,217.21
in general payments reported to CMS, 2019-2025
15 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $161 · 2021: $53.28 · 2022: $133 · 2023: $158 · 2024: $153 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $161.96 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $142.86 | 2019-2024 | |
| Allergan, INC. | $125.69 | 2020 | |
| Tactile Systems Technology INC | $72.82 | 2019-2025 | Flexitouch Plus, Nimbl |
| Novo Nordisk INC | $61.95 | 2019-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $34.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.53 | 2019 | |
| Zyla Life Sciences, INC. | $27.91 | 2019 | |
| Glaxosmithkline, LLC. | $25.48 | 2025 | Shingrix, Arexvy |
| Phadia US INC. | $20.94 | 2024 | Immunocap |
| Astellas Pharma US INC | $20.54 | 2024 | Veozah |
| Viiv Healthcare Company | $18.69 | 2024 | Apretude |
| Cleerly, INC. | $13.40 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Idorsia Pharmaceuticals US INC | $13.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.